DK3319611T3 - Oxysteroler og fremgangsmåder til anvendelse deraf - Google Patents

Oxysteroler og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number: DK3319611T3
Authority: DK; Denmark
Prior art keywords: oxysterols; procedures
Prior art date: 2015-07-06

Application number

DK16821924.4T

Other languages

English (en)

Inventor

Francesco G Salituro

Albert Jean Robichaud

Botella Gabriel Martinez

Original Assignee

Sage Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-07-06

Filing date

2016-07-06

Publication date

2021-04-12

2016-07-06 Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc

2021-04-12 Application granted granted Critical

2021-04-12 Publication of DK3319611T3 publication Critical patent/DK3319611T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Anesthesiology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK16821924.4T 2015-07-06 2016-07-06 Oxysteroler og fremgangsmåder til anvendelse deraf DK3319611T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562189048P	2015-07-06	2015-07-06
US201662280394P	2016-01-19	2016-01-19
PCT/US2016/041168 WO2017007836A1 (en)	2015-07-06	2016-07-06	Oxysterols and methods of use thereof

Publications (1)

Publication Number	Publication Date
DK3319611T3 true DK3319611T3 (da)	2021-04-12

Family

ID=57686105

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK16821924.4T DK3319611T3 (da)	2015-07-06	2016-07-06	Oxysteroler og fremgangsmåder til anvendelse deraf
DK21151891.5T DK3828194T3 (da)	2015-07-06	2016-07-06	Oxysteroler og fremgangsmåder til anvendelse deraf

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK21151891.5T DK3828194T3 (da)	2015-07-06	2016-07-06	Oxysteroler og fremgangsmåder til anvendelse deraf

Country Status (30)

Country	Link
US (4)	US10201550B2 (da)
EP (3)	EP3828194B1 (da)
JP (4)	JP2018519351A (da)
KR (2)	KR102703602B1 (da)
CN (2)	CN113292623A (da)
AU (3)	AU2016289967B2 (da)
BR (2)	BR112018000129B1 (da)
CA (1)	CA2991214C (da)
CO (1)	CO2018000660A2 (da)
CY (1)	CY1124496T1 (da)
DK (2)	DK3319611T3 (da)
ES (2)	ES3035617T3 (da)
FI (1)	FI3828194T3 (da)
HR (1)	HRP20210526T8 (da)
HU (1)	HUE053778T2 (da)
IL (2)	IL256710B2 (da)
LT (1)	LT3319611T (da)
MA (2)	MA42410B1 (da)
MD (1)	MD3319611T2 (da)
MX (2)	MX376833B (da)
PE (1)	PE20180483A1 (da)
PH (2)	PH12021551134A1 (da)
PL (2)	PL3828194T3 (da)
PT (2)	PT3319611T (da)
RS (1)	RS61718B1 (da)
RU (2)	RU2021100620A (da)
SG (1)	SG10202010553XA (da)
SI (1)	SI3319611T1 (da)
SM (1)	SMT202100226T1 (da)
WO (1)	WO2017007836A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2012304412A1 (en)	2011-09-08	2014-03-27	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
PT2968369T (pt)	2013-03-13	2018-12-05	Sage Therapeutics Inc	Esteroides neuroativos e métodos para o seu uso
WO2015195967A1 (en)	2014-06-18	2015-12-23	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
EP3166613A4 (en)	2014-07-09	2018-02-21	Duke University	Compositions and methods for the repair of myelin
EP3319610A4 (en)	2015-07-06	2019-03-06	Sage Therapeutics, Inc.	OXYSTEROLS AND METHOD OF USE THEREOF
CN113292623A (zh)	2015-07-06	2021-08-24	萨奇治疗股份有限公司	孕甾醇及其使用方法
PT3319612T (pt)	2015-07-06	2021-08-24	Sage Therapeutics Inc	Oxisteróis e métodos de utilização dos mesmos
ES2921010T3 (es) *	2016-04-01	2022-08-16	Sage Therapeutics Inc	Oxisteroles y procedimientos de uso de los mismos
US10752653B2 (en)	2016-05-06	2020-08-25	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
ES2884071T3 (es)	2016-07-07	2021-12-10	Sage Therapeutics Inc	24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
ES2935057T3 (es) *	2016-09-30	2023-03-01	Sage Therapeutics Inc	C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
EP4105223B1 (en)	2016-10-18	2025-04-30	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
BR112019008032A2 (pt)	2016-10-18	2019-09-03	Sage Therapeutics, Inc.	oxiesteróis e métodos de uso dos mesmos
EP3568138B1 (en) *	2017-01-13	2025-03-05	Duke University	Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
US10857163B1 (en)	2019-09-30	2020-12-08	Athenen Therapeutics, Inc.	Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
CA3223179A1 (en)	2021-06-11	2022-12-15	Sage Therapeutics, Inc.	Neuroactive steroid for the treatment of alzheimer's disease
CN113667734B (zh) *	2021-07-16	2022-05-24	四川大学华西医院	Shank3片段序列甲基化检测试剂在制备精神分裂症诊断试剂盒中的用途
WO2023028278A2 (en) *	2021-08-25	2023-03-02	Sage Therapeutics, Inc.	Positive nmda-modulating compounds and methods of use thereof
WO2023083979A1 (en) *	2021-11-10	2023-05-19	Umecrine Ab	3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
EP4447953A1 (en)	2021-12-13	2024-10-23	Sage Therapeutics, Inc.	Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
CA3249933A1 (en) *	2022-01-28	2025-01-16	Cholesgen (Shanghai) Co., Ltd.	STEROID COMPOUND, ITS PREPARATION PROCESS AND ITS USE
WO2024229297A1 (en) *	2023-05-02	2024-11-07	Sage Therapeutics, Inc.	Lymphatic system-targeting compounds
WO2025020190A1 (zh) *	2023-07-27	2025-01-30	珂阑(上海)医药科技有限公司	甾类化合物、其制备方法和应用
CN119371475B (zh) *	2023-07-27	2025-11-04	珂阑(上海)医药科技有限公司	甾类化合物、其制备方法和应用
TW202508555A (zh) *	2023-07-27	2025-03-01	大陸商珂闌(上海)醫藥科技有限公司	甾類化合物、其製備方法和應用
WO2025221732A1 (en) *	2024-04-15	2025-10-23	Sage Therapeutics, Inc.	Nmda receptor-modulating compounds and methods of use thereof

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2259698A (en)	1938-05-07	1941-10-21	Rare Chemicals Inc	Physiologically effective substance and process of preparing same
US2594323A (en)	1948-07-22	1952-04-29	Upjohn Co	24-substituted delta 5-cholene-3, 24-diols
US2673206A (en)	1950-06-07	1954-03-23	Schering Corp	25-ethinyl steroids
US3079385A (en)	1961-01-24	1963-02-26	Roussel Uclaf	Novel process of preparation of polyhydroxylated pregnanes
US3206459A (en)	1962-10-19	1965-09-14	Syntex Corp	10alpha-pregnan-19-ol derivatives
JPS5324071B2 (da)	1974-04-30	1978-07-18
US4071625A (en)	1974-05-13	1978-01-31	Richardson-Merrell Inc.	19-Oxygenated-5α-androstanes for the enhancement of libido
CH628907A5 (en)	1975-10-10	1982-03-31	Hoffmann La Roche	Process for the preparation of 24,25-dihydroxycholesterol derivatives
JPS5840960B2 (ja)	1976-12-28	1983-09-08	帝人株式会社	ヒドロキシコレステロ−ル立体異性体間の相互変換法
US4183852A (en)	1977-07-18	1980-01-15	Kaiser Emil T	Process for preparing 25-hydroxycholesterol
JPS54163565A (en)	1978-06-09	1979-12-26	Teijin Ltd	24255epoxyy3beta 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production
US4174345A (en)	1978-08-01	1979-11-13	Kaiser Emil T	Synthesis of steroids
US4269777A (en)	1979-05-21	1981-05-26	Wisconsin Alumni Research Foundation	Isotopically labeled vitamin D derivatives and processes for preparing same
JPS5735597A (en)	1980-08-13	1982-02-26	Teijin Ltd	25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation
US4358406A (en)	1981-07-27	1982-11-09	Wisconsin Alumni Research Foundation	26,26,26,27,27,27-Hexafluoro-1α,25-dihydroxycholecalciferol and process for preparing same
JPS61254599A (ja)	1985-05-07	1986-11-12	Sumitomo Pharmaceut Co Ltd	コレステロ−ルのフツ素誘導体
DE3664909D1 (en)	1985-05-30	1989-09-14	Taisho Pharmaceutical Co Ltd	Vitamin d3 derivatives
JPS62187485A (ja)	1986-02-13	1987-08-15	Teijin Ltd	２４，２５−エポキシコレステロ−ル類の製造法
EP0382790A4 (en)	1987-08-25	1991-03-27	Kelvin W. Gee	Compositions and methods for alleviating stress, anxiety and seizure activity
US5232917A (en)	1987-08-25	1993-08-03	University Of Southern California	Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP0701444B1 (en)	1993-05-24	2010-04-07	Purdue Pharma Ltd.	Methods and compositions for inducing sleep
IL110309A0 (en)	1993-07-15	1994-10-21	Univ Kentucky Res Found	A method of protecting against neuron loss
DE4338316A1 (de)	1993-11-10	1995-05-11	Jenapharm Gmbh	Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
BR9506779A (pt)	1994-02-14	1997-10-14	Cocensys Inc	Composto composição farmacéutica método para modular o complexo ionóforo receptor gaba-cloreto em um paciente animal pela ligação ao sitio neuroesteróide no dito complexo método para tratar ou evitar estresse ou ansiedade em um paciente animal método para aliviar ou evitar isônia pms ou pnd em um paciente animal método para tratar ou evitar perturbacões na disposicão de ánimo em um paciente animal e método para induzir anestesia em um paciente animal
TW385308B (en)	1994-03-04	2000-03-21	Merck & Co Inc	Prodrugs of morpholine tachykinin receptor antagonists
US5595996A (en)	1994-10-25	1997-01-21	Merck & Co., Inc.	7-substituted 4-aza cholanic acid derivatives and their use
BR9509764A (pt)	1994-11-23	1998-07-07	Cocensys Inc	Série androstano e pregnano para modulação alostérica de receptor de gaba
JPH08268917A (ja)	1995-03-31	1996-10-15	D D S Kenkyusho:Kk	癌組織への移行性の高い制癌剤
PL185523B1 (pl)	1995-06-06	2003-05-30	Cocensys Inc	Neuroaktywne steroidy z grupy pochodnych androstanu i pregnanu oraz kompozycja farmaceutyczna
US5792635A (en)	1995-06-07	1998-08-11	Magainin Pharmaceuticals, Inc.	Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
CA2224866A1 (en)	1995-06-23	1997-01-09	Novo Nordisk A/S	Meiosis regulating compounds
US6645953B2 (en)	1995-06-23	2003-11-11	Novo Nordisk A/S	Meiosis regulating compounds
US5888996A (en)	1995-07-26	1999-03-30	Trustees Of Boston University	Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
JP4313435B2 (ja)	1995-07-24	2009-08-12	トラスティーズオブボストンユニバーシティー	プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制
US5841272A (en)	1995-12-20	1998-11-24	Sundstrand Corporation	Frequency-insensitive current sensor
WO1997042215A1 (en)	1996-05-06	1997-11-13	Bionumerik Pharmaceuticals, Inc.	Process for preparing 27-hydroxy cholesterol and related derivatives
JPH09328498A (ja)	1996-06-10	1997-12-22	Teijin Ltd	２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体
WO1998005337A1 (en)	1996-08-01	1998-02-12	Cocensys, Inc.	Use of gaba and nmda receptor ligands for the treatment of migraine headache
DE19635525A1 (de)	1996-08-20	1998-02-26	Schering Ag	7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US6122371A (en)	1997-07-22	2000-09-19	Atwell; Ronald C.	Apparatus for protecting coin-operated telephones from vandalism and larceny
WO1999058497A1 (en)	1998-05-11	1999-11-18	Novo Nordisk A/S	Substituted guanidines and diaminonitroethenes, their preparation and use
KR20010043558A (ko)	1998-05-13	2001-05-25	한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느	감수분열 조절 화합물
US8541600B2 (en) *	1998-11-24	2013-09-24	Harbor Therapeutics, Inc.	11-aza, 11-thia and 11-oxa sterol compounds and compositions
DE19917930A1 (de)	1999-04-15	2000-10-19	Schering Ag	Ent-Steroide als selektiv wirksame Estrogene
YU77701A (sh)	1999-04-29	2005-07-19	Euro-Celtique S.A.	3-α-HIDROKSI-3Гџ-METOKSIMETIL-21-HETEROCIKLIČNO SUPSTITUISANI STEROIDI SA ANESTETIČKIM DEJSTVOM
US6376530B1 (en)	1999-05-10	2002-04-23	Merck & Co., Inc.	Cyclic amidines useful as NMDA NR2B antagonists
GB9910934D0 (en)	1999-05-11	1999-07-14	Res Inst Medicine Chem	Chemical compounds
CN1111167C (zh)	1999-10-22	2003-06-11	中国科学院上海有机化学研究所	3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途
CN1098273C (zh)	1999-11-12	2003-01-08	中国科学院上海有机化学研究所	高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物
GB0000228D0 (en)	2000-01-06	2000-03-01	Phytopharm Plc	Fluoro substituted sapogenins and their use
GB0019290D0 (en)	2000-08-04	2000-09-27	Symphar Sa	Methods for inducing apolipoprotein E secretion
GR1003861B (el)	2000-12-29	2002-04-11		Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
GB0107822D0 (en)	2001-03-28	2001-05-23	Phytopharm Plc	Sapogenin derivatives their synthesis and use methods based upon their use
ATE375994T1 (de)	2001-05-03	2007-11-15	Univ Chicago	Leber x rezeptoragonisten
US20070197484A1 (en)	2001-05-03	2007-08-23	Ching Song	Method of treating disorder related to high cholesterol concentration
TW200300078A (en)	2001-11-08	2003-05-16	Univ Chicago	Method of treating disorder related to high cholesterol concentration
EP1461028A4 (en)	2001-12-07	2007-07-25	Univ California	TREATMENT FOR AGE-RELATED MACULAR AGENCY
KR101130212B1 (ko)	2002-03-27	2012-04-13	파이토팜 피엘씨	사포게닌 및 그 유도체의 치료 방법 및 사용법
ATE424211T1 (de)	2002-03-27	2009-03-15	Phytopharm Plc	Therapeutische verwendung von sapogeninen
GB0216621D0 (en)	2002-07-17	2002-08-28	Imaging Res Solutions Ltd	Imaging compounds
US6933312B2 (en)	2002-10-07	2005-08-23	Agouron Pharmaceuticals, Inc.	Pyrazole derivatives
US20060160853A1 (en)	2002-11-22	2006-07-20	Mccauley John A	2-[(4-Benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists
AU2003288231A1 (en)	2002-12-13	2004-07-09	Bayer Healthcare Ag	Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
FR2850023B1 (fr)	2003-01-17	2007-04-06	Mapreg	Medicaments pour le systeme nerveux
US20050142192A1 (en)	2003-10-15	2005-06-30	Wyeth	Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
GB0403889D0 (en)	2004-02-21	2004-03-24	Univ Edinburgh	Uses of er-beta modulators
US8604011B2 (en)	2004-09-27	2013-12-10	The Regents Of The University Of California	Therapy for treatment of chronic degenerative brain diseases and nervous system injury
US20070032464A1 (en)	2004-10-08	2007-02-08	Shutsung Liao	Methods of treating cancers
DE602005025391D1 (de)	2004-11-01	2011-01-27	Seo Hong Yoo	Verfahren und zusammensetzungen zur verringerung der neurodegeneration bei amyotrophischer lateralsklerose
JP2009528291A (ja)	2006-02-27	2009-08-06	ザリージェンツオブザユニバーシティオブカリフォルニア	オキシステロール化合物及びヘッジホッグ経路
CN101164540A (zh)	2006-08-03	2008-04-23	中山大学	海洋甾体化合物在制备治疗神经元损伤药物中的应用
GB0619860D0 (en)	2006-10-06	2006-11-15	Birkeland Innovasjon As	Treatment of insulin resistance and disorders associated therewith
WO2008057468A1 (en)	2006-11-02	2008-05-15	Curis, Inc.	Small organic molecule regulators of cell proliferation
HUE036410T2 (hu)	2006-11-21	2018-07-30	Asarina Pharma Ab	Pregnán és androsztán szteroidok alkalmazása CNS rendellenességek kezelésére szolgáló gyógyszerkészítmény elõállítására
AU2008331808B2 (en)	2007-03-16	2014-08-21	The Regents Of The University Of California	Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling
CN101842355A (zh)	2007-06-20	2010-09-22	奥斯拜客斯制药有限公司	作为纤维化抑制剂的取代的n-芳基吡啶酮
GB0712494D0 (en)	2007-06-27	2007-08-08	Isis Innovation	Substrate reduction therapy
EP2207542A2 (en)	2007-11-06	2010-07-21	N.V. Organon	A method of hormone suppression in humans
WO2009090063A1 (en)	2008-01-16	2009-07-23	Jado Technologies Gmbh	Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
EP2244577B1 (en)	2008-01-25	2012-10-31	Merck Sharp & Dohme Corp.	Quinolizidinone m1 receptor positive allosteric modulators
WO2009137843A2 (en)	2008-05-09	2009-11-12	Emory University	Nmda receptor antagonists for the treatment of neuropsychiatric disorders
WO2010065709A2 (en)	2008-12-03	2010-06-10	Amin Khan	Hydroxamic acid derivatives, preparation and therapeutic uses thereof
WO2010075282A1 (en)	2008-12-22	2010-07-01	University Of Washington	Molecular inhibitors of the wnt/beta-catenin pathway
WO2010088408A2 (en)	2009-01-28	2010-08-05	Emory University	Subunit selective nmda receptor antagonists for the treatment of neurological conditions
US8829213B2 (en)	2009-07-29	2014-09-09	The University Of Chicago	Liver X receptor agonists
WO2011028794A2 (en)	2009-09-01	2011-03-10	Lazarus Therapeutics, Inc.	Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
FR2953138B1 (fr)	2009-12-02	2015-10-16	Assist Publ Hopitaux Marseille	Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus
WO2011092127A1 (en)	2010-01-26	2011-08-04	Bayer Schering Pharma Aktiengesellschaft	14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring
KR101692275B1 (ko)	2010-02-11	2017-01-04	노오쓰웨스턴 유니버시티	２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US8247436B2 (en)	2010-03-19	2012-08-21	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF
GB201008047D0 (en)	2010-05-14	2010-06-30	Ge Healthcare Ltd	Method of synthesis
US20120035156A1 (en)	2010-08-09	2012-02-09	Daniela Alberati	Combination of glyt1 compound with antipsychotics
US8969525B2 (en)	2010-11-09	2015-03-03	Enzo Life Sciences, Inc.	Hydroxycholesterol immunoassay
US20150031655A1 (en)	2011-04-15	2015-01-29	University Of North Dakota	Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
US20140335050A1 (en)	2011-05-27	2014-11-13	The General Hospital Corporation	Methods, compositions, and kits for the treatment of cancer
CA2843436A1 (en)	2011-07-29	2013-02-07	The Regents Of The University Of California	Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors
AU2012304412A1 (en)	2011-09-08	2014-03-27	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
MX360706B (es)	2011-10-07	2018-11-14	Takeda Pharmaceuticals Co	Compuestos de 1-arilcarbonil-4-oxi-piperidina utiles para el tratamiento de enfermedades neurodegenerativas.
PT2766380T (pt)	2011-10-14	2019-07-29	Sage Therapeutics Inc	Compostos de 19-nor pregnano 3,3-dissubstituídos, composições e seus usos
US20150119327A1 (en)	2012-04-25	2015-04-30	The Regents Of The University Of California	Drug screening platform for rett syndrome
WO2014025942A1 (en)	2012-08-09	2014-02-13	Emory University	Nmda receptor modulators and uses related thereto
WO2014028942A2 (en)	2012-08-17	2014-02-20	Trueex Group Llc	Interoffice bank offered rate financial product and implementation
KR102400891B1 (ko)	2012-12-18	2022-05-20	워싱톤 유니버시티	신경활성 19-알콕시-17-치환된 스테로이드, 그의 전구약물, 및 그를 사용한 치료 방법
CN105073119A (zh)	2013-01-23	2015-11-18	司菲埃拉制药私人有限公司	用于线粒体生物发生和与线粒体功能障碍或耗竭相关的疾病的新颖11β-羟基类固醇化合物
WO2014120786A1 (en)	2013-01-29	2014-08-07	Naurex, Inc.	Spiro-lactam nmda receptor modulators and uses thereof
PT2968369T (pt)	2013-03-13	2018-12-05	Sage Therapeutics Inc	Esteroides neuroativos e métodos para o seu uso
HK1220472A1 (zh) *	2013-03-13	2017-05-05	萨奇治疗股份有限公司	神经活性类固醇、组合物、及其用途
HK1222565A1 (zh)	2013-09-25	2017-07-07	范安德尔研究所	高效糖皮質激素
MX388168B (es)	2014-02-08	2025-03-19	Genentech Inc	Un anticuerpo anti-amiloide beta (a?) monoclonal humanizado para usarse en el tratamiento de enfermedad de alzheimer.
WO2015195967A1 (en)	2014-06-18	2015-12-23	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
EP3166613A4 (en)	2014-07-09	2018-02-21	Duke University	Compositions and methods for the repair of myelin
US10016095B2 (en) *	2014-10-03	2018-07-10	Progressive International Corporation	Salad spinner
CA2963938C (en)	2014-10-07	2023-10-24	Sage Therapeutics, Inc.	Neuroactive compounds and methods of use thereof
PT3319612T (pt)	2015-07-06	2021-08-24	Sage Therapeutics Inc	Oxisteróis e métodos de utilização dos mesmos
EP3319610A4 (en)	2015-07-06	2019-03-06	Sage Therapeutics, Inc.	OXYSTEROLS AND METHOD OF USE THEREOF
CN113292623A (zh)	2015-07-06	2021-08-24	萨奇治疗股份有限公司	孕甾醇及其使用方法
GB2557875A (en)	2015-09-02	2018-07-04	Univ Swansea	Diagnostic methods and kits
ES2921010T3 (es)	2016-04-01	2022-08-16	Sage Therapeutics Inc	Oxisteroles y procedimientos de uso de los mismos
US10752653B2 (en)	2016-05-06	2020-08-25	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
ES2884071T3 (es)	2016-07-07	2021-12-10	Sage Therapeutics Inc	24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
AU2017296295B2 (en)	2016-07-11	2022-02-24	Sage Therapeutics, Inc.	C7, C12, and C16 substituted neuroactive steroids and their methods of use
ES2935057T3 (es)	2016-09-30	2023-03-01	Sage Therapeutics Inc	C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA
BR112019008032A2 (pt)	2016-10-18	2019-09-03	Sage Therapeutics, Inc.	oxiesteróis e métodos de uso dos mesmos
EP4105223B1 (en)	2016-10-18	2025-04-30	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
AU2018234828A1 (en)	2017-03-15	2019-09-19	Modernatx, Inc.	Lipid nanoparticle formulation
BR112019027458A2 (pt)	2017-06-23	2020-07-07	Intercept Pharmaceuticals, Inc.	métodos e intermediários para a preparação de derivados de ácidos biliares
US20190160078A1 (en)	2017-11-10	2019-05-30	Marinus Pharmaceuticals, Inc.	Ganaxolone for use in treating genetic epileptic disorders
MX2023013072A (es)	2021-05-04	2024-03-19	Sage Therapeutics Inc	Esteroide neuroactivo para el tratamiento del deterioro cognitivo leve asociado a la enfermedad de parkinson.
CA3223179A1 (en)	2021-06-11	2022-12-15	Sage Therapeutics, Inc.	Neuroactive steroid for the treatment of alzheimer's disease

2016
- 2016-07-06 CN CN202110670292.XA patent/CN113292623A/zh active Pending
- 2016-07-06 JP JP2018500417A patent/JP2018519351A/ja not_active Withdrawn
- 2016-07-06 CA CA2991214A patent/CA2991214C/en active Active
- 2016-07-06 PT PT168219244T patent/PT3319611T/pt unknown
- 2016-07-06 US US15/742,425 patent/US10201550B2/en active Active
- 2016-07-06 KR KR1020187003210A patent/KR102703602B1/ko active Active
- 2016-07-06 ES ES21151891T patent/ES3035617T3/es active Active
- 2016-07-06 PH PH1/2021/551134A patent/PH12021551134A1/en unknown
- 2016-07-06 EP EP21151891.5A patent/EP3828194B1/en active Active
- 2016-07-06 RS RS20210461A patent/RS61718B1/sr unknown
- 2016-07-06 MD MDE20180512T patent/MD3319611T2/ro unknown
- 2016-07-06 BR BR112018000129-5A patent/BR112018000129B1/pt active IP Right Grant
- 2016-07-06 WO PCT/US2016/041168 patent/WO2017007836A1/en not_active Ceased
- 2016-07-06 RU RU2021100620A patent/RU2021100620A/ru unknown
- 2016-07-06 PE PE2018000034A patent/PE20180483A1/es unknown
- 2016-07-06 MX MX2018000282A patent/MX376833B/es active IP Right Grant
- 2016-07-06 CN CN201680051035.5A patent/CN108135912B/zh active Active
- 2016-07-06 PT PT211518915T patent/PT3828194T/pt unknown
- 2016-07-06 PL PL21151891.5T patent/PL3828194T3/pl unknown
- 2016-07-06 PL PL16821924T patent/PL3319611T3/pl unknown
- 2016-07-06 MA MA42410A patent/MA42410B1/fr unknown
- 2016-07-06 ES ES16821924T patent/ES2865258T3/es active Active
- 2016-07-06 IL IL256710A patent/IL256710B2/en unknown
- 2016-07-06 EP EP16821924.4A patent/EP3319611B1/en active Active
- 2016-07-06 SM SM20210226T patent/SMT202100226T1/it unknown
- 2016-07-06 DK DK16821924.4T patent/DK3319611T3/da active
- 2016-07-06 AU AU2016289967A patent/AU2016289967B2/en active Active
- 2016-07-06 BR BR122021005552-1A patent/BR122021005552B1/pt active IP Right Grant
- 2016-07-06 LT LTEP16821924.4T patent/LT3319611T/lt unknown
- 2016-07-06 SI SI201631146T patent/SI3319611T1/sl unknown
- 2016-07-06 HU HUE16821924A patent/HUE053778T2/hu unknown
- 2016-07-06 SG SG10202010553XA patent/SG10202010553XA/en unknown
- 2016-07-06 MA MA055097A patent/MA55097A/fr unknown
- 2016-07-06 HR HRP20210526TT patent/HRP20210526T8/hr unknown
- 2016-07-06 IL IL305404A patent/IL305404A/en unknown
- 2016-07-06 PH PH1/2018/500065A patent/PH12018500065B1/en unknown
- 2016-07-06 RU RU2018104278A patent/RU2744267C2/ru active
- 2016-07-06 KR KR1020247029533A patent/KR20240137111A/ko active Pending
- 2016-07-06 FI FIEP21151891.5T patent/FI3828194T3/fi active
- 2016-07-06 MX MX2020011449A patent/MX390302B/es unknown
- 2016-07-06 DK DK21151891.5T patent/DK3828194T3/da active
- 2016-07-06 EP EP25170341.9A patent/EP4609866A3/en active Pending
2018
- 2018-01-24 CO CONC2018/0000660A patent/CO2018000660A2/es unknown
- 2018-12-20 US US16/227,099 patent/US10765685B2/en active Active
2020
- 2020-07-29 US US16/942,245 patent/US20210145848A1/en not_active Abandoned
2021
- 2021-01-08 JP JP2021002172A patent/JP2021054864A/ja not_active Withdrawn
- 2021-04-13 CY CY20211100316T patent/CY1124496T1/el unknown
- 2021-08-20 AU AU2021218228A patent/AU2021218228B2/en active Active
2022
- 2022-06-08 JP JP2022093073A patent/JP7602513B2/ja active Active
2024
- 2024-01-16 AU AU2024200268A patent/AU2024200268A1/en active Pending
- 2024-03-13 US US18/603,816 patent/US12268697B2/en active Active
- 2024-12-06 JP JP2024213240A patent/JP2025026573A/ja active Pending

Also Published As

Publication number	Publication date
BR112018000129A2 (pt)	2018-09-04
CN108135912A (zh)	2018-06-08
AU2024200268A1 (en)	2024-02-01
EP3828194A1 (en)	2021-06-02
RU2744267C2 (ru)	2021-03-04
EP3319611A1 (en)	2018-05-16
RU2018104278A (ru)	2019-08-06
HRP20210526T1 (hr)	2021-05-28
SG10202010553XA (en)	2020-12-30
SMT202100226T1 (it)	2021-05-07
US20210145848A1 (en)	2021-05-20
US20180200267A1 (en)	2018-07-19
KR20240137111A (ko)	2024-09-19
PL3828194T3 (pl)	2025-09-22
JP2025026573A (ja)	2025-02-21
PH12018500065B1 (en)	2022-11-04
JP2021054864A (ja)	2021-04-08
EP3319611A4 (en)	2019-03-06
MX2020011449A (es)	2022-02-28
NZ738847A (en)	2024-05-31
US20190125764A1 (en)	2019-05-02
MA42410A (fr)	2018-05-16
PE20180483A1 (es)	2018-03-07
BR122021005552B1 (pt)	2024-01-02
FI3828194T3 (fi)	2025-07-17
AU2016289967B2 (en)	2021-09-09
SI3319611T1 (sl)	2021-08-31
LT3319611T (lt)	2021-05-10
CN108135912B (zh)	2021-07-02
CA2991214A1 (en)	2017-01-12
MA55097A (fr)	2022-01-05
US12268697B2 (en)	2025-04-08
EP4609866A3 (en)	2025-10-22
PT3828194T (pt)	2025-07-17
AU2021218228A1 (en)	2021-09-09
KR102703602B1 (ko)	2024-09-06
MX390302B (es)	2025-03-19
MX376833B (es)	2025-03-07
CY1124496T1 (el)	2022-07-22
KR20180026743A (ko)	2018-03-13
US20240277733A1 (en)	2024-08-22
EP3319611B1 (en)	2021-01-20
IL305404A (en)	2023-10-01
PH12018500065A1 (en)	2018-07-09
CA2991214C (en)	2024-04-30
US10765685B2 (en)	2020-09-08
AU2021218228B2 (en)	2023-11-16
MA42410B1 (fr)	2021-04-30
WO2017007836A1 (en)	2017-01-12
MD3319611T2 (ro)	2021-06-30
BR112018000129B1 (pt)	2024-01-09
BR122023021450A2 (pt)	2023-12-26
RU2021100620A (ru)	2021-01-29
NZ777726A (en)	2024-05-31
PH12021551134A1 (en)	2024-03-25
PT3319611T (pt)	2021-04-22
IL256710B2 (en)	2024-01-01
ES3035617T3 (en)	2025-09-05
IL256710A (en)	2018-03-29
HRP20210526T8 (hr)	2021-08-20
JP2018519351A (ja)	2018-07-19
EP3828194B1 (en)	2025-04-16
CO2018000660A2 (es)	2018-07-10
DK3828194T3 (da)	2025-06-30
HUE053778T2 (hu)	2021-07-28
MX2018000282A (es)	2018-03-08
AU2016289967A1 (en)	2018-02-01
RU2018104278A3 (da)	2019-10-31
JP2022120062A (ja)	2022-08-17
PL3319611T3 (pl)	2021-07-12
IL256710B1 (en)	2023-09-01
RS61718B1 (sr)	2021-05-31
EP4609866A2 (en)	2025-09-03
CN113292623A (zh)	2021-08-24
US10201550B2 (en)	2019-02-12
ES2865258T3 (es)	2021-10-15
JP7602513B2 (ja)	2024-12-18

Publication	Publication Date	Title
DK3319611T3 (da)	2021-04-12	Oxysteroler og fremgangsmåder til anvendelse deraf
DK3436022T3 (da)	2022-06-20	Oxysteroler og fremgangsmåder til anvendelse heraf
DK3280441T3 (da)	2021-11-15	Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3319612T3 (da)	2021-08-23	Oxysteroler og fremgansmåder til anvendelse derfor
DK3258951T3 (da)	2020-04-06	Anti-pvrig antistoffer og fremgangsmåder for anvendelse
DK3380101T3 (da)	2021-04-26	Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK3354282T3 (da)	2021-03-08	Glycan-terapeutiske midler og relaterede fremgangsmåder deraf
DK3264955T3 (da)	2020-08-31	Blandeanordning og fremgangsmåde
DK3265947T3 (da)	2021-10-04	Fremgangsmåde og system til kryptering
DK3200615T3 (da)	2019-08-19	Kaloriefrie sødestoffer og fremgangsmåder til syntetisering
DK3116911T3 (da)	2019-09-30	Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse
DK3368534T3 (da)	2021-02-15	Valbenazin-ditosylat og polymorfer deraf
DK3337549T3 (da)	2019-09-16	Kateteranordninger med ventiler og tilhørende fremgangsmåder.
DK3265043T3 (da)	2023-01-30	Hjælpemiddel til patienttransport og -træning
DK3218358T3 (da)	2021-08-30	Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3166937T3 (da)	2019-10-21	Antiproliferative forbindelser og fremgangsmåder til anvendelse deraf
DK3210977T3 (da)	2019-07-01	Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf
DK3015526T3 (da)	2021-01-18	Hydrofluorolefinbaseret sammensætning og anvendelse deraf
DK3103715T3 (da)	2020-03-23	Styreindretning og styringsfremgangsmåde dertil
DK3342571T3 (da)	2020-09-07	Blandeindretning og blandefremgangsmåde
DK3256598T3 (da)	2021-01-11	Svampestammer og anvendelsesfremgangsmåder
DK3384079T3 (da)	2020-07-20	Fibrøs konstruktion og fremgangsmåder i forbindelse hermed
DK3346056T3 (da)	2021-12-13	Rengøringssystem og fremgangsmåde
DK3265641T3 (da)	2020-03-16	Stigørenhed og fremgangsmåde
DK2964767T3 (da)	2020-03-23	Toksingener og fremgangsmåder til anvendelse deraf